SCHEMBL276606

SCHEMBL276606

CCCCCCC(CCC)OC=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 2/20 0.42
ADH1C P00326 2/20 0.42
ADH1A P07327 2/20 0.42
ADH4 P08319 2/20 0.42
ADH7 P40394 2/20 0.42
CTSK P43235 1/20 0.41
OPRM1 P35372 1/20 0.38
TSHR P16473 1/20 0.38
SMPD1 P17405 3/20 0.37
MAPT P10636 2/20 0.37
TRPA1 O75762 1/20 0.37
DDAH1 O94760 1/20 0.37
GAPDH P04406 1/20 0.37
GPR84 Q9NQS5 3/20 0.36
FDPS P14324 3/20 0.36
FFAR1 O14842 1/20 0.36
ZDHHC7 Q9NXF8 1/20 0.36
EPHX1 P07099 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18187977 1.00 ADH1B (0.42) ADH1BADH1CADH1AADH4ADH7
SCHEMBL18188007 1.00 ADH1B (0.42) ADH1BADH1CADH1AADH4ADH7
SCHEMBL3007421 0.98 CTSK (0.42) ADH1BADH1CADH1AADH4ADH7
SCHEMBL17040069 0.96 ADH1B (0.45) ADH1BADH1CADH1AADH4ADH7
SCHEMBL18188028 0.96 ADH1B (0.45) ADH1BADH1CADH1AADH4ADH7
SCHEMBL24654117 0.96 ADH1B (0.45) ADH1BADH1CADH1AADH4ADH7
SCHEMBL18782878 0.96 ADH1B (0.45) ADH1BADH1CADH1AADH4ADH7
SCHEMBL17123651 0.96 ADH1B (0.45) ADH1BADH1CADH1AADH4ADH7
SCHEMBL1614822 0.96 ADH1B (0.45) ADH1BADH1CADH1AADH4ADH7
SCHEMBL17040070 0.96 ADH1B (0.45) ADH1BADH1CADH1AADH4ADH7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9580636-B2 Secondary esters, methods of making, and uses thereof CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2017-02-28 US claimed
US-20160319178-A1 Secondary Esters, Methods of Making, and Uses Thereof CHEVRON PHILLIPS CHEMICAL COMPANY LP 2016-11-03 US claimed
WO-2016176243-A1 SECONDARY ESTERS, METHODS OF MAKING, AND USES THEREOF CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2016-11-03 WO claimed
US-20250189532-A1 1,6-DIYNE COMPOUND, ITS PREPARATION METHOD, AND PRODUCTS OBTAINED USING 1,6-DIYNE COMPOUND AS RAW MATERIAL AND THEIR APPLICATIONS FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER, CHINESE ACADEMY OF SCIENCES (CN) 2025-06-12 US disclosed
CN-116730882-B Structure of 1, 6-diyne compound and application thereof 中国科学院福建物质结构研究所 2025-05-13 CN disclosed
EP-4488262-A1 1,6-DIYNE COMPOUND AND PREPARATION METHOD THEREFOR, AND PRODUCT OBTAINED USING 1,6-DIYNE COMPOUND AS RAW MATERIAL AND USE THEREOF Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences (CN) 2025-01-08 EP disclosed
CN-116730882-A Structure of 1, 6-diyne compound and application thereof 中国科学院福建物质结构研究所 2023-09-12 CN disclosed
WO-2023165217-A1 1,6-DIYNE COMPOUND AND PREPARATION METHOD THEREFOR, AND PRODUCT OBTAINED USING 1,6-DIYNE COMPOUND AS RAW MATERIAL AND USE THEREOF 中国科学院福建物质结构研究所 2023-09-07 WO disclosed
US-9580636-B2 Secondary esters, methods of making, and uses thereof CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2017-02-28 US disclosed
EP-2439204-B1 HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER NISSAN CHEMICAL IND LTD (JP) 2017-01-04 EP disclosed
US-9527828-B2 Method for expanding hematopoietic stem cells using heterocyclic compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-12-27 US disclosed
US-7351841-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-04-01 US disclosed
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2008-01-31 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed
EP-1819692-A1 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS Nissan Chemical Industries, Ltd. (JP) 2007-08-22 EP disclosed
CN-1798739-A 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators NISSAN CHEMICAL IND LTD (JP) 2006-07-05 CN disclosed
WO-2006062240-A1 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2006-06-15 WO disclosed
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2006-05-04 US disclosed
EP-1636192-A1 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS Nissan Chemical Industries, Ltd. (JP) 2006-03-22 EP disclosed
WO-2004108683-A1 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NR2C2, ROR1, NR0B2 ADH1B 2159/4885ADH1C 3407/4885ADH1A 2945/4885
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 ADH1B 2139/4885ADH1C 3391/4885ADH1A 2907/4885
US-20250189532-A1 1,6-DIYNE COMPOUND, ITS PREPARATION METHOD, AND PRODUCTS OBTAINED USING 1,6-DIYNE COMPOUND AS RAW MATERIAL AND THEIR APPLICATIONS HAO2, HAO1, TH ADH1B 1521/4885ADH1C 1133/4885ADH1A 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.